Decrease in cell surface sialic acid in etoposide-treated Jurkat cells and the role of cell surface sialidase.
The present study investigated the mechanism underlying alterations of cell surface sugar chains of Jurkat cells by inducing apoptosis with etoposide, an inhibitor of topoisomerase II. Within 3 h of etoposide treatment, flowcytometric analysis revealed a decrease in Maackia amurensis agglutinin recognized alpha2,3-linked sialic acid moieties and an increase in Ricinus communis agglutinin recognized galactose. The results suggested that asialo-sugar chains on glycoconjugates were rapidly induced on the etoposide-treated cell surface. To clarify the desialylation mechanism, we studied alpha2,3-sialyltransferase mRNA expression and the activity of sialidase on the cell surface during etoposide-induced apoptosis. The expression of hST3Gal III and hST3Gal IV mRNAs were down-regulated and sialidase activity on the cell surface increased threefold within 2 h of etoposide treatment. Moreover, the decrease in alpha2,3-linked sialic acid levels was significantly suppressed in the presence of 2,3-dehydro-2-deoxy-N-acetylneuraminic acid, an inhibitor of sialidase. These results suggested that activation or exposure of sialidase on the cell surface was induced by etoposide treatment and was the main cause of the decrease in sialic acids.
Department of Clinical Chemistry, School of Pharmaceutical Sciences, Toho University, Funabashi, Chiba, Japan. yutaro@phar.toho-u.ac.jp
Y
Y
Azuma
A
A
Taniguchi
K
K
Matsumoto
D017209:Apoptosis / Q000187:drug effects; D015152:Blotting, Northern; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology*; D005434:Flow Cytometry; D005690:Galactose / Q000032:analysis / Q000378:metabolism; D006801:Humans; D019169:Jurkat Cells / Q000187:drug effects; D019158:N-Acetylneuraminic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D009439:Neuraminidase / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism*; D012794:Sialic Acids / Q000032:analysis / Q000378:metabolism*; D012799:Sialyltransferases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D059005:Topoisomerase II Inhibitors
D004791:Enzyme Inhibitors; D012794:Sialic Acids; D059005:Topoisomerase II Inhibitors; C036137:2-deoxy-2,3-dehydro-N-acetylneuraminic acid; D005047:Etoposide; D012799:Sialyltransferases; C029156:N-acetyllactosaminide alpha-2,3-sialyltransferase; D009439:Neuraminidase; D019158:N-Acetylneuraminic Acid; D005690:Galactose